BNTCライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	19 742.00
平均出来高	82 838.00
時価総額	17.89M
EPS	$0 ( 2024-02-12 )
次の収益日	( $-0.780 ) 2024-05-13
Last Dividend	$0.0450 ( 2018-06-01 )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0330 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Banks Jerel A.	Buy	466 554	Options (right to buy)
2024-03-06	Boston Megan	Buy	200 004	Options (right to buy)
2023-12-06	Smith Edward F	Buy	35 000	Options (right to buy)
2023-12-06	Francis Peter	Buy	35 000	Options (right to buy)
2023-12-06	Buchi J Kevin	Buy	35 000	Options (right to buy)

INSIDER POWER
100.00
Last 38 transactions
Buy: 2 361 696 \| Sell: 57 465

ボリューム相関

長: -0.17 (neutral)

短: -0.39 (neutral)

Signal:(48.426) Neutral

Benitec Biopharma Inc 相関

10 最も正の相関
RNLX	0.862
TTSH	0.842
BAFN	0.831
OVLY	0.829
VIOT	0.826
GGAL	0.826
ASLE	0.824
CASH	0.823
BOOM	0.82
TELA	0.818

10 最も負の相関
MBCN	-0.811

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Benitec Biopharma Inc 相関 - 通貨/商品

0.15
( neutral )

0.10
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.14
( neutral )

-0.43
( neutral )

Benitec Biopharma Inc 財務諸表

Annual	2023
収益:	$75 000.00
総利益:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2023
収益:	$75 000.00
総利益:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2022
収益:	$73 000.00
総利益:	$64 000.00 (87.67 %)
EPS:	$-38.62

FY	2021
収益:	$59 000.00
総利益:	$-64 000.00 (-108.47 %)
EPS:	$-3.23

Financial Reports:

No articles found.

Benitec Biopharma Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Benitec Biopharma Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0450	2018-06-01
Last Dividend	$0.0450	2018-06-01
Next Dividend	$0	N/A
Payout Date	2018-06-08
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0450	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$0.0450	0.01%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-358.57	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.024	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.55	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.55	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0198	-1.500	9.67	-10.00	[0 - 0.6]
interestCoverageTTM	-1 446.13	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
freeCashFlowPerShareTTM	-7.01	2.00	-3.51	-7.01	[0 - 20]
debtEquityRatioTTM	0.0273	-1.500	9.89	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-355.61	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-42.71	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00286	0.800	-3.31	-2.65	[0.5 - 2]
Total Score				-1.934

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.813	1.000	-0.183	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.01	2.00	-2.34	-7.01	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00690	1.500	-3.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-296.16	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.45

Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.